Get started

Enzo Biochem, Inc

At close
No trades
See on super-charts
Overview
News Ideas Financials Technicals

ENZ chart

Key stats

Market capitalization
109.621MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.55USD

About Enzo Biochem, Inc

ISIN
US2941001024
Sector
Health Technology
Industry
Biotechnology
Website
enzo.com
CEO
Hamid Erfanian
Headquarters
New York
Employees
520
Founded
1976

Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which focuses on delivering and applying advanced technology capabilities to produce affordable reliable products and services that enable customers to meet their clinical needs. It operates through the following segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Therapeutics segment conducts research and development activities for therapeutic drug candidates. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

Ideas

$ENZ is gonna fall todayPupm&Dump trading strategy idea. $ENZ is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $3,48; stop-loss — $3,67; take-profit — $3,12. Do not view thi
Enzo Biochem spiked on 43x average volumeEnzo Biochem spiked on 43x average volume. This is highly volatile price action. Enzo Biochem (ENZ) reported Quarter January 2021 earnings of $0.09 per share on revenue of $31.5 million. Revenue grew 62.3% on a year-over-year basis. Enzo Biochem Inc is engaged in research, development, manufacturing
ENZ Spike Higher After FDA EUA For Its AMPIPROBEShares Of Enzo Life Sciences Spike Higher After Co. Gets FDA Emergency Use Authorization For Its AMPIPROBE Coronavirus Test System Enzo Biochem (NYSE:ENZ) soared 21% yesterday as its Ampiprobe SARS-CoV-2 Test System was granted Emergency Use Authorization by the FDA in a letter. The letter stated,
ENZ just getting noticed -not your typical stupid Corona coThis is the real deal from a fundamental perspective 1.00 in cash no debt, activist bought 12% of co. and put 2 people on the board before Corona ever became a thing and they bought their 12% position at $3.07 , 400 patents 80mm in revenue and insiders have bought between 2.20-3.65 - oh and yes
Long
ENZO BIOCHEM INC - NYSE: $ENZ FlaggingLast week, ENZO BIOCHEM INC - NYSE:ENZ broke to higher ground and in the process, recaptured its 200 DMA out of a rounding bottom and now finds itself digesting/consolidating the move within a Flag pattern on lower volume as is evidenced in the Daily chart above. In addition, ENZ is now trading
1

See all ideas 

News flow

Keep readingKeep reading

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Financials

Income Statement
Balance Sheet
Cash Flow
Earnings
Next:—
Revenue

Explore more features and data

Learn more about our full range of powerful features including the best charts on the web.Learn more